Tiziana Life Sciences Ltd (NASDAQ:TLSA) chief medical officer and chief operating officer Matthew Davis speaks to Thomas Warner from Proactive after the clinical-stage biopharmaceutical company announced an update on the company’s progress in treating non-active secondary progressive multiple sclerosis (MS).
The latest six-month PET scan data reveals improvements in five out of six patients, echoing the positive results from the three-month scans. This breakthrough aligns with the drug’s hypothesis, as published in the Proceedings of the National Academy of Science, which suggests the drug works by stabilising the brain’s innate immunity. From a business perspective, Davis suggests the findings are significant.
In the US, there’s no FDA-approved treatment for this specific MS type, affecting approximately 200,000 patients. Tiziana Life Sciences is gearing up for its phase 2a programme, focusing on PET change as a primary endpoint. Davis also highlights that he addressed the importance of targeting neuroinflammation in MS and Alzheimer’s during a keynote speech in Milan this week.
Proactive UK Ltd
+44 20 7989 0813
View source version on newsdirect.com: https://newsdirect.com/news/tiziana-life-sciences-reports-six-month-pet-scan-results-for-ms-patients-545441035
This article is for the purposes of solicitation subscriptions for this website. This website expects to generate new advertisement revenue resulting from the distribution of this article. The amount of which is unknown at this time. This website or it’s authors do not own any shares of Tiziana Life Sciences plc (TLSA) and does not buy, sell, or trade any shares of (TLSA). This article does not provide a professional analysis of a (TLSA) financial position. (TLSA) financial position and all other information regarding the featured Company should be verified directly with (TLSA). Please read our full disclaimer for more detailed information.